Prosthetic joint infections - Pipeline Insight, 2024

This “Prosthetic joint infections- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prosthetic joint infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Prosthetic joint infections: Understanding

Prosthetic joint infections: Overview

Prosthetic joint infection (PJI), also referred to as periprosthetic infection, is defined as an infection involving the joint prosthesis and adjacent tissue. The clinical manifestations of PJI vary depending upon the virulence of the organism, the mode of initiation of infection, the host immune response, the soft tissue structure surrounding the joint, and the joint involved.

Underlying the pathogenesis of prosthetic joint infection is the simple fact that prostheses are foreign bodies, and they can promote the formation of biofilm by several notable organisms. These organisms form communities in a hydrated polymeric matrix on implant surfaces and necrotic tissues. These bacterial aggregates, with their inherent resistance to antimicrobial agents, are the main culprits for prosthetic joint infection. Biofilm is a thin film of microorganism-embedded glycocalyx (exopolysaccharides), which often coats the surface of the prosthesis and creates a barrier against antimicrobial agents. Also, certain forms of Staphylococcus aureus, a notable player in prosthetic joint infections, may form small colony variants that often grow slowly and are associated with recurrent and difficult-to-treat infections. It takes four weeks for the maturation of biofilms. Sources of infection are: Haematogenous spread with the most commonly encountered foci (e.g., Staphylococcus aureus, Klebsiella, Escherichia coli, Streptococcus pneumonia, etc.) for infection along with the most commonly involved organisms, Direct spread through a route communicating the prosthesis and the outer environment e.g., Sinus tract or open periprosthetic fracture or Local spread from a nearby septic focus e.g., osteomyelitis or soft tissue infection.

The diagnosis of PJI is based upon a combination of clinical findings, laboratory results from peripheral blood and synovial fluid, microbiological data, histological evaluation of periprosthetic tissue, intraoperative inspection, and/or radiographic results. A missed prosthetic joint infection or one that is not treated appropriately can result in persistence of infection with deletarious consequences including disability and impaired quality of life. Treatment for PJI involves surgical intervention and medical therapy with an aim to eradicate the infection, restore pain-free function of the infected joint, and minimize PJI-related morbidity and mortality for the patient.

Prosthetic joint infections- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prosthetic joint infections pipeline landscape is provided which includes the disease overview and Prosthetic joint infections treatment guidelines. The assessment part of the report embraces, in depth Prosthetic joint infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prosthetic joint infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Prosthetic joint infections R&D. The therapies under development are focused on novel approaches to treat/improve Prosthetic joint infections.

Prosthetic joint infections Emerging Drugs Chapters

This segment of the Prosthetic joint infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Prosthetic joint infections Emerging Drugs

TNP 2092: TenNor TherapeuticsTNP-2092 is a multi-targeting drug conjugate that exerts antibacterial activity by inhibiting three essential targets in bacterial biofilms: RNA polymerase, DNA gyrase and topoisomerase IV. TNP-2092 has demonstrated strong bactericidal activity, a low frequency for the development of resistance, and an excellent safety profile. The drug is in Phase II clinical developmental studies for the treatment of bacterial infections and skin and soft tissue infections. In January 2020, TenNor Therapeutics received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.

PLG0206: PeptilogicsPLG0206 is an intravenous antibiotic derived from the cationic antibiotic peptide (eCAP) platform. PLG0206 works by targeting and disrupting bacterial membranes leading to the death of bacterial cells. PLG0206 has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for the treatment of prosthetic joint infections (PJI). Currently, the drug is in the Phase I stage of its development for the treatment of PJI.

Prosthetic joint infections: Therapeutic Assessment

This segment of the report provides insights about the different Prosthetic joint infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Prosthetic joint infections

• There are approx. 5+ key companies which are developing the therapies for Prosthetic joint infections. The companies which have their Prosthetic joint infections drug candidates in the most advanced stage, i.e. phase II include, TenNor Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Prosthetic joint infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Prosthetic joint infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Prosthetic joint infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prosthetic joint infections drugs.

Prosthetic joint infections Report Insights

• Prosthetic joint infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Prosthetic joint infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Prosthetic joint infections drugs?
• How many Prosthetic joint infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prosthetic joint infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Prosthetic joint infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Prosthetic joint infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Adaptive Phage Therapeutics
• TenNor Therapeutics
• Peptilogics

Key Products

• Bacteriophage
• TNP 2092
• PLG0206

This product will be delivered within 1-3 business days.